de cotation: Italian
S.p.A. is the first Italian managed-care company resulting from the
build up process sponsored by the closed end fund Cape Natexis.
The company is led by Simone Cimino and has been listed on the Expandi
market of the Italian Stock Exchange since August 1st 2006.
The Arkimedica Group operates in the managed care sector and propose to
aggregate a network of successful companies in the health and medical
industry. It serves as a reference point for products and services of
the health care industry.
The Arkimedica Group is active in the sector of health care and medical
products through four synergic divisions: the Contract Division
specializing in the turnkey supply of furniture for hospital buildings
and nursing homes (Cla Group);
the Care Division operating in the management of assisted nursing homes
(Sogespa Group); the Medical Devices Division active in the production
and sales of sole-use medical devices (Delta Med Group) and the
Equipment Division is in charge of planning, production, and sales of
pharmaceutical and hospital sterilization equipment (Icos Group).
to the diversified but synergic nature of the sectors in which the
controlled companies operate, Arkimedica is capable of making the most
of the important complementary features of these groups, creating the
possibility to widen its own clientele portfolio thanks to long-held
contacts of said groups.
Representing more than 30 units of entrepreneur-managers, Arkimedica
presents itself as a counterpart for other companies in the sector
willing to join the first Italian public company operating in the
April 24th, 2008
Important acquisition by Contract Division
Arkimedica announces that it has stipulated, through its subsidiary Cla
S.p.A, an agreement to
acquire 70% of Euroclinic Srl, a company based in Castelbolognese (RA)
that manufactures and
sells chairs for the otolaryngology, podology, and gynaecology sectors.
Arkimedica forecasts that Euroclinic will achieve a turnover of Euro
4.5 million this year,
approximately 80% of which generated by foreign sales, with an EBITDA
of Euro 600,000.
The acquisition price is Euro 2 million, which, considering the
company’s net financial position,
envisages an Enterprise Value/EBITDA multiple of approximately 6x.
Maurilio Longo (who will remain a shareholder with 30% of the share
capital) will continue to
manage the company, having shown excellent management skills in
achieving the company’s
current results in only five years.
Simone Cimino, Arkimedica’s President, says, “I am very pleased with
Arkimedica Group’s Contract Division will expand its product range and
synergies among Group companies, especially with regard to foreign